Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024

/PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today said that they expect Leqembi sales to total JPY 56.5 billion...

Related Keywords

Stockholm ,Sweden ,China ,Japan ,Swedish ,Lecanemab Leqembi ,Jiang Millington ,Oskar Bosson ,Alzheimer Network Trials Unit ,National Institutes Of Health ,Alzheimer Clinical Trial Consortium ,National Institute On ,Vp Communications ,European Union ,Washington University School Of Medicine ,Director Corporate Communication ,Social Media ,New England Journal ,Clinical Trial Consortium ,National Institute ,National Institutes ,Tau Nexgen ,Dominantly Inherited ,Washington University School ,Commercialization Agreement ,Nasdaq Stockholm Large ,